Driving reinvestment in R&D for antibiotics and advocating their responsible use

News

DRIVE-AB Partner Laxminarayan Urges UN to Set Global Targets for AMR

DRIVE-AB Work Package 1C co-leader Ramanan Laxminarayan has co-authored an article ahead of the United Nations (UN) General Assembly meeting on antimicrobial resistance titled, "Achieving global targets for antimicrobial resistance". Published in Science on 18 August 2016, the article urges the UN to promote and set global targets, funding and governance for antimicrobial resistance (AMR). Please click here to read the full article.    ...
Read more

DRIVE-AB Partners Help Lead on New International Public-Private Partnership CARB-X to Fund Antibiotic Preclinical R&D

DRIVE-AB welcomes today's announcement of the establishment of The Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X), one of the world’s largest public-private partnerships focused on tackling antibiotic resistance. This five year public-private partnership will provide non-equity, non-dilutive funding to preclinical companies pursuing antibacterial products. The consortium is directed by DRIVE-AB partner Kevin Outterson, with DRIVE-AB Work Package 1A co-leader Barry Eisenstein leading the Scientific Advisory Board and Work Package 1C co-leader John Rex serving as Chief Strategy Officer. This new project is in alignment with DRIVE-AB's pillars of access and sustainable use and offers a great opportunity for collaboration in the field of antibiotic...
Read more

DRIVE-AB Metrics & Indicators of Responsible Antibiotic Use Included in ECDC’s Draft EU Guidelines of Human Antibiotic Use

The European Commission has asked the European Centre for Disease Prevention and Control (ECDC) to develop draft EU guidelines on the prudent use of antimicrobials in human medicine, including generic principles of good practice on the appropriate use of antimicrobial agents in human medical practice in the EU. These draft guidelines will be a key contribution to support the European Commission in its aim to produce a finalised EU guidelines document. DRIVE-AB Work Package 1A's work on indicators and metrics of responsible antibiotic use (available here) have been considered in the drafting of this document and are referred to on page 10 of...
Read more

EMA Recommends Countries Reduce Colistin Use in Animals

The European Medicines Agency (EMA) has recommended that colistin-containing medicines should only be used as a second line treatment in animals and that their sales should be minimised across all European Union (EU) Member States to reduce the risk of antimicrobial resistance. The advice updates EMA guidance from 2013 and takes into account comments made by stakeholders during a public consultation that ended on 26 June 2016. The European Commission asked for this update in response to the discovery of a new mechanism of resistance in bacteria to colistin caused by the mcr-1 gene. Please click here to read the...
Read more